CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Shares Shorted: Short Interest Up 136.4% in October

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) saw a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 3,450,760 shares, a growth of 136.4% from the September 30th total of 1,459,951 shares. Based on an average daily trading volume, of 342,939 shares, the days-to-cover ratio is presently 10.1 days. Approximately 7.0% of the shares of the company are short sold.

Insiders Place Their Bets

In other CAMP4 Therapeutics news, Director Andrew Schwab sold 400,000 shares of CAMP4 Therapeutics stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the sale, the director directly owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. The trade was a 16.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Richard Young acquired 16,378 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the acquisition, the director directly owned 186,388 shares in the company, valued at approximately $307,540.20. The trade was a 9.63% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders acquired 46,031 shares of company stock valued at $99,051 and sold 593,613 shares valued at $2,504,037. 21.69% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CAMP4 Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Jupiter Topco LLC acquired a new position in CAMP4 Therapeutics during the second quarter worth $27,581,000. 5AM Venture Management LLC acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at about $25,647,928. Trails Edge Capital Partners LP acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at about $8,446,935. BlackRock Inc. acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at about $7,185,000. Finally, SummitTX Capital L.P. acquired a new stake in shares of CAMP4 Therapeutics in the first quarter valued at about $1,497,000.

CAMP4 Therapeutics Stock Performance

Shares of NASDAQ CAMP opened at $3.96 on Friday. The company has a market capitalization of $248.49 million, a PE ratio of -1.71 and a beta of 0.27. The company’s fifty day moving average price is $3.89 and its 200 day moving average price is $4.24. CAMP4 Therapeutics has a 1 year low of $2.90 and a 1 year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. On average, equities analysts expect that CAMP4 Therapeutics will post -0.68 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of CAMP4 Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. UBS Group set a $15.00 price target on CAMP4 Therapeutics in a research report on Friday, August 14th. Chardan Capital reduced their price objective on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, September 29th. Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a report on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.44.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.